Vivos Therapeutics, Inc. (NASDAQ:VVOS) Q4 2022 Results Conference Call March 30, 2023 5:00 PM ET

Company Participants

Julie Gannon - Investor Relations Officer

Kirk Huntsman - Chairman and Chief Executive Officer

Brad Amman - Chief Financial Officer

Conference Call Participants

Scott Henry - ROTH Capital Partners

Lucas Ward - Ascendiant Capital Markets

Operator

Good day, everyone, and welcome to the Vivos Therapeutics Fourth Quarter and Full Year 2022 Earnings Conference Call. At this time participants are in a listen-only mode. A question-and-answer session will follow management’s remarks. This conference call is being recorded, and a replay of today's call will be available on the Investor Relations section of Vivos' website and will remain posted for the next 30 days.

I will now hand the call over to Julie Gannon, Vivos' Investor Relations Officer for introductions and the reading of the Safe harbor. Please go ahead.

Julie Gannon

Thank you, operator. Hello everyone and welcome to our conference call. A copy of our earnings press release is available on the Investor Relations section of our website at www.vivos.com.

With us on today's call are Kirk Huntsman, Vivos' Chairman and Chief Executive Officer; and Brad Amman, Chief Financial Officer. Today, we'll review the highlights and financial results for the fourth quarter of 2022, as well as more recent developments and Vivos' plan for the remainder of 2023. Following these formal remarks, we will be happy to answer your questions.

Words such as aim -- oh, I'm sorry, I would also like to remind everyone that today's call will contain certain forward-looking statements from our management, made within the meaning of Section 27A on the Securities Act of 1933 as amended and Section 21E of the Securities and Exchange Act of 1934 as amended, concerning future events. Words such as aim, may, could, should, projects, expects, intends, plans, believes, anticipates, hopes, estimates and variations of such words and similar expressions are intended to identify as forward-looking statements. These statements involve significant known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant risks, uncertainties and contingencies, many of which are beyond the Company's control.

Actual results, including without limitation, the results of Vivos' growth strategies, operational plans, including sales, marketing, product acquisition and integration, research and development, regulatory initiatives, cost savings plans and plans to generate revenue, as well as potential results of operations and operating metrics and other matters to be addressed by Vivos' management in this conference call, may differ materially and adversely from those expressed or implied by such forward-looking statements.